Literature DB >> 19596079

Revealing promiscuous drug-target interactions by chemical proteomics.

Marcus Bantscheff1, Arjen Scholten, Albert J R Heck.   

Abstract

The (poly-)pharmacological activities of a drug can only be understood if its interactions with cellular components are comprehensively characterized. Mass spectrometry-based chemical proteomics approaches have recently emerged as powerful tools for the characterization of drug-target interactions in samples from cell lines and tissues. At the same time, off-target activities can be identified. This information can contribute toward optimization of candidate drug molecules and reduction of side effects. In this review, we describe recent advances in chemical proteomics and outline potential applications in drug discovery.

Mesh:

Substances:

Year:  2009        PMID: 19596079     DOI: 10.1016/j.drudis.2009.07.001

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN: 1359-6446            Impact factor:   7.851


  26 in total

1.  Integrating molecular diagnostics into anticancer drug discovery.

Authors:  István Peták; Richárd Schwab; László Orfi; László Kopper; György Kéri
Journal:  Nat Rev Drug Discov       Date:  2010-06-07       Impact factor: 84.694

2.  Targeted data acquisition for improved reproducibility and robustness of proteomic mass spectrometry assays.

Authors:  Mikhail M Savitski; Frank Fischer; Toby Mathieson; Gavain Sweetman; Manja Lang; Marcus Bantscheff
Journal:  J Am Soc Mass Spectrom       Date:  2010-01-25       Impact factor: 3.109

Review 3.  Recent progress on cheminformatics approaches to epigenetic drug discovery.

Authors:  Zoe Sessions; Norberto Sánchez-Cruz; Fernando D Prieto-Martínez; Vinicius M Alves; Hudson P Santos; Eugene Muratov; Alexander Tropsha; José L Medina-Franco
Journal:  Drug Discov Today       Date:  2020-09-30       Impact factor: 7.851

Review 4.  Chemical Proteomic Approaches Targeting Cancer Stem Cells: A Review of Current Literature.

Authors:  Hye Jin Jung
Journal:  Cancer Genomics Proteomics       Date:  2017 Sep-Oct       Impact factor: 4.069

5.  A miniaturized chemical proteomic approach for target profiling of clinical kinase inhibitors in tumor biopsies.

Authors:  Ivo Chamrád; Uwe Rix; Alexey Stukalov; Manuela Gridling; Katja Parapatics; André C Müller; Soner Altiok; Jacques Colinge; Giulio Superti-Furga; Eric B Haura; Keiryn L Bennett
Journal:  J Proteome Res       Date:  2013-08-20       Impact factor: 4.466

6.  Identification of drug targets in vitro and in living cells by soluble-nanopolymer-based proteomics.

Authors:  Lianghai Hu; Anton Iliuk; Jacob Galan; Michael Hans; W Andy Tao
Journal:  Angew Chem Int Ed Engl       Date:  2011-03-31       Impact factor: 15.336

7.  Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes.

Authors:  Marcus Bantscheff; Carsten Hopf; Mikhail M Savitski; Antje Dittmann; Paola Grandi; Anne-Marie Michon; Judith Schlegl; Yann Abraham; Isabelle Becher; Giovanna Bergamini; Markus Boesche; Manja Delling; Birgit Dümpelfeld; Dirk Eberhard; Carola Huthmacher; Toby Mathieson; Daniel Poeckel; Valérie Reader; Katja Strunk; Gavain Sweetman; Ulrich Kruse; Gitte Neubauer; Nigel G Ramsden; Gerard Drewes
Journal:  Nat Biotechnol       Date:  2011-01-23       Impact factor: 54.908

8.  Multiplexed mass cytometry profiling of cellular states perturbed by small-molecule regulators.

Authors:  Bernd Bodenmiller; Eli R Zunder; Rachel Finck; Tiffany J Chen; Erica S Savig; Robert V Bruggner; Erin F Simonds; Sean C Bendall; Karen Sachs; Peter O Krutzik; Garry P Nolan
Journal:  Nat Biotechnol       Date:  2012-09       Impact factor: 54.908

Review 9.  Target deconvolution techniques in modern phenotypic profiling.

Authors:  Jiyoun Lee; Matthew Bogyo
Journal:  Curr Opin Chem Biol       Date:  2013-01-18       Impact factor: 8.822

10.  Human DDX3 protein is a valuable target to develop broad spectrum antiviral agents.

Authors:  Annalaura Brai; Roberta Fazi; Cristina Tintori; Claudio Zamperini; Francesca Bugli; Maurizio Sanguinetti; Egidio Stigliano; José Esté; Roger Badia; Sandra Franco; Miguel A Martinez; Javier P Martinez; Andreas Meyerhans; Francesco Saladini; Maurizio Zazzi; Anna Garbelli; Giovanni Maga; Maurizio Botta
Journal:  Proc Natl Acad Sci U S A       Date:  2016-04-26       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.